Last reviewed · How we verify
Biomarkers
At a glance
| Generic name | Biomarkers |
|---|---|
| Sponsor | Ciusss de L'Est de l'Île de Montréal |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- Diagnostic and PROgnostic BIOmarkers Before and After Kidney Transplantation (N/A)
- A Phase I Study of Antisense Bcl-2 Oligonucleotide (G3139) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors (Phase 1)
- One Year, Single Arm, Open Label, Multicenter, Phase IV Study Using Multimodal Imaging to Guide Disease Activity Assessment Through Innovative Early Predictive Anatomical Biomarkers of Fluid Resolutio (Phase 4)
- A Phase IV Open-Label Clinical Trial to Evaluate the Efficacy of Ikervis® on Clinical Parameters and Molecular/Cellular Biomarkers in Dry Eye Patients With Severe Keratitis Who Have Not Improved Despi (Phase 4)
- Molecular Correlates of Response to C225 (Erbitux or Cetuximab) in Combination With Cisplatin and Definitive Radiation in Unresectable Stage IV Squamous Cell Carcinoma of the Head and Neck (E3303): A (N/A)
- A Phase II Study of Targeted Brachytherapy for Low Risk Prostate Cancer Patients (Phase 2)
- A Retrospective Study to Identify New "Omics" Biomarkers of Chronic/Persistent Low Back Pain (N/A)
- NCT02411474 (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biomarkers CI brief — competitive landscape report
- Biomarkers updates RSS · CI watch RSS
- Ciusss de L'Est de l'Île de Montréal portfolio CI